Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 230

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Hematopoietic Cell Transplantation After Nonmyeloablative Conditioning for Advanced Chronic Lymphocytic Leukemia

Open access
Sorror, Mohamed L., Maris, Michael B., Sandmaier, Brenda M., Storer, Barry E., Stuart, Monic J., Hegenbart, Ute, Agura, Edward, Chauncey, Thomas R., Leis, Jose, Pulsipher, Michael, McSweeney, Peter, Radich, Jerald P., Bredeson, Christopher, Bruno, Benedetto, Langston, Amelia, Loken, Michael R., Al-Ali, Haifa, Blume, Karl G., Storb, Rainer, Maloney, David G.·2005·Journal of Clinical Oncology

Abstract

Purpose: Patients with chemotherapy-refractory chronic lymphocytic leukemia (CLL) have a short life expectancy. The aim of this study was to analyze the outcome of patients with advanced CLL when treated with nonmyeloablative conditioning and hematopoietic cell transplantation (HCT). Patients and Methods: Sixty-four patients diagnosed with advanced CLL were treated with nonmyeloablative conditioning (2 Gy total-body irradiation with [n = 53] or without [n = 11] fludarabine) and HCT from related (n = 44) or unrelated (n = 20) donors. An adapted form of the Charlson comorbidity index was used to assess pretransplantation comorbidities. Results: Sixty-one of 64 patients had sustained engraftment, whereas three patients rejected their grafts. The incidences of grades 2, 3, and 4 acute and chronic graft-versus-host disease were 39%, 14%, 2%, and 50%, respectively. Three patients who underwent transplantation in complete remission (CR) remained in CR. The overall response rate among 61 patients with measurable disease was 67% (50% CR), whereas 5% had stable disease. All patients with morphologic CR who were tested by polymerase chain reaction (n = 11) achieved negative molecular results, and one of these patients subsequently experienced disease relapse. The 2-year incidence of relapse/progression was 26%, whereas the 2-year relapse and nonrelapse mortalities were 18% and 22%, respectively. Two-year rates of overall and disease-free survivals were 60% and 52%, respectively. Unrelated HCT resulted in higher CR and lower relapse rates than related HCT, suggesting more effective graft-versus-leukemia activity. Conclusion: CLL is susceptible to graft-versus-leukemia effects, and allogeneic HCT after nonmyeloablative conditioning might prolong median survival for patients with advanced CLL.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2005.04.569

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 230

Metadata

Authors
Sorror, M. L., Maris, M. B., Sandmaier, B. M., Storer, B. E., Stuart, M. J., Hegenbart, U., Agura, E., Chauncey, T. R., Leis, J., Pulsipher, M., McSweeney, P., Radich, J. P., Bredeson, C., Bruno, B., Langston, A., Loken, M. R., Al-Ali, H., Blume, K. G., Storb, R., & Maloney, D. G.
Venue
Journal of Clinical Oncology
Published
2005-06-01
Volume
23
Issue
16
Pages
3819-3829
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2153747389
Cited by
230
References
1
FWCI
15.44
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Hematopoietic Cell Transplantation After Nonmyeloablative Conditioning for Advanced Chronic Lymphocytic Leukemia. https://app.cochat.ai/papers/10.1200/jco.2005.04.569
The paper
Sorror, M. L., Maris, M. B., Sandmaier, B. M., Storer, B. E., Stuart, M. J., Hegenbart, U., Agura, E., Chauncey, T. R., Leis, J., Pulsipher, M., McSweeney, P., Radich, J. P., Bredeson, C., Bruno, B., Langston, A., Loken, M. R., Al-Ali, H., Blume, K. G., Storb, R., & Maloney, D. G. (2005). Hematopoietic Cell Transplantation After Nonmyeloablative Conditioning for Advanced Chronic Lymphocytic Leukemia. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2005.04.569

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.